Dachaigh › Purpura Thrombocytopenic Idiopathic › Massachusetts
Sgrùdaidhean clionaigeach Purpura Thrombocytopenic Idiopathic ann an Massachusetts
Tha 6 sgrùdaidhean airson Purpura Thrombocytopenic Idiopathic a’ lorg phàirtichean aig làraichean ann an Massachusetts.
Bailtean ann an Massachusetts
Teacsa sgrùdaidh oifigeil (Beurla)
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Massachusetts General Hospital, Boston
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 18 Sult 2026 · NCT06722235Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia
- Beth Israel Deaconess Medical Center, Boston
A’ fastadhÌre 2
Aoisean 18 gu 80 · Gach gnè · Air ùrachadh 14 Sult 2026 · NCT07095127Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
- Beth Israel Deaconess Medical Center, Boston
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 14 Sult 2026 · NCT07104565A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Massachusetts General Hospital, Boston
- University of Massachusetts Chan Medical School, Worcester
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 9 Sult 2026 · NCT06948318Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
- Massachusetts General Hospital Cancer Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Mass General Brigham Cancer Institute, Danvers
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Ògmh 2026 · NCT07007962Cognitive Dysfunction in Chronic and Persistent Immune Thrombocytopenia
- Massachusetts General Hospital, Boston
A’ fastadhSgrùdadh amharc
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 10 Gearr 2025 · NCT06817395Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.